Cargando…

Pharmacogenetic Association between XRCC1 Polymorphisms and Response to Platinum-Based Chemotherapy in Asian Patients with NSCLC: A Meta-Analysis

BACKGROUND: Platinum-based chemotherapy plays an antitumor role by damaging DNA. X-ray repair crosscomplementing protein 1 (XRCC1) participates in DNA repair and thus affects the sensitivity to platinum drugs. Two polymorphisms of XRCC1, rs25487 (Arg399Gln) and rs1799782 (Arg194Trp), have been widel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Ningning, Ouyang, Yushu, Chang, Jianlan, Liu, Ping, Tian, Xiangyang, Yu, Junyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603545/ https://www.ncbi.nlm.nih.gov/pubmed/33150172 http://dx.doi.org/10.1155/2020/3520764

Ejemplares similares

Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Patients
por: Yin, Ji-Ye, et al.
Publicado: (2012)

XRCC3 Thr241Met Polymorphism and Clinical Outcomes of NSCLC Patients Receiving Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis
por: Shen, Xiao-yong, et al.
Publicado: (2013)

Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statement
por: Li, Dan-Juan, et al.
Publicado: (2017)

Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy
por: Yuan, Zhengrong, et al.
Publicado: (2015)

A Meta-Analysis for Association of XRCC1, XRCC2 and XRCC3 Polymorphisms with Susceptibility to Thyroid Cancer
por: Mandegari, Mohammad, et al.
Publicado: (2021)

XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy: A systematic review and MOOSE-compliant meta-analysis
por: Zhang, Zhuo, et al.
Publicado: (2018)

MicroRNA-429 acts as a tumor suppressor in colorectal cancer by targeting high mobility group box 3
por: Tian, Xiangyang, et al.
Publicado: (2021)

Polymorphisms of CCNB1 Associated With the Clinical Outcomes of Platinum-Based Chemotherapy in Chinese NSCLC Patients
por: Liu, Di, et al.
Publicado: (2017)

Association of XRCC1, XRCC2 and XRCC3 Gene Polymorphism with Esophageal Cancer Risk
por: Kaur, Jagjeet, et al.
Publicado: (2020)

ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy
por: Liblab, Salisa, et al.
Publicado: (2020)

AB143. Pharmacogenetic association between XRCC1 polymorphisms and improved outcomes in bladder cancer patients following intravesical instillation of epirubicin
por: Li, Pengchao, et al.
Publicado: (2016)

Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population
por: Wu, Xiaoqing, et al.
Publicado: (2023)

Polymorphism of XRCC1, XRCC3, and XPD Genes and Risk of Chronic Myeloid Leukemia
por: Bănescu, Claudia, et al.
Publicado: (2014)

Polymorphisms of the XRCC1, XRCC3, & XPD genes, and colorectal cancer risk: a case-control study in Taiwan
por: Yeh, Chih-Ching, et al.
Publicado: (2005)

A miR‐15a related polymorphism affects NSCLC prognosis via altering ERCC1 repair to platinum‐based chemotherapy
por: Xue, Ping, et al.
Publicado: (2022)

Meta-Analysis of Therapy of Cinobufacini Capsule Adjunct with First-Line Platinum-Based Chemotherapy for the Treatment of Advanced NSCLC
por: Peng, Wenpan, et al.
Publicado: (2021)

Polymorphisms of XRCC3 and XRCC7 and Colorectal Cancer Risk in Khorasan Razavi Province, Iran
por: Mehrzad, Jamshid, et al.
Publicado: (2019)

Association of XRCC3, XRCC4, BAX, and BCL-2 Polymorphisms with the Risk of Breast Cancer
por: Ozoran, Emre, et al.
Publicado: (2022)

Association between XRCC1 and XRCC3 Polymorphisms with Lung Cancer Risk: A Meta-Analysis from Case-Control Studies
por: Huang, Guohua, et al.
Publicado: (2013)

A pharmacogenetics study of platinum-based chemotherapy in lung cancer: ABCG2 polymorphism and its genetic interaction with SLC31A1 are associated with response and survival
por: Wang, Liyan, et al.
Publicado: (2021)

IMpower132: Atezolizumab plus platinum‐based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients
por: Nishio, Makoto, et al.
Publicado: (2021)

Meta-analysis of XRCC1 polymorphism and risk of female reproductive system cancer
por: Yang, Na-Na, et al.
Publicado: (2017)

Effect of XPC polymorphisms on the response to platinum-based chemotherapy: a meta-analysis
por: Xie, Chenyao, et al.
Publicado: (2019)

BMP-4 Genetic Variants and Protein Expression Are Associated with Platinum-Based Chemotherapy Response and Prognosis in NSCLC
por: Xian, Sun, et al.
Publicado: (2014)

XRCC3 Thr241Met Is Associated with Response to Platinum-Based Chemotherapy but Not Survival in Advanced Non-Small Cell Lung Cancer
por: Qiu, Mantang, et al.
Publicado: (2013)

WISP1 Polymorphisms Contribute to Platinum-Based Chemotherapy Toxicity in Lung Cancer Patients
por: Chen, Juan, et al.
Publicado: (2014)

Platinum-Resistant Ovarian Cancer Is Vulnerable to the cJUN-XRCC4 Pathway Inhibition
por: Xu, Manman, et al.
Publicado: (2022)

A Comprehensive Evaluation of the Association between Polymorphisms in XRCC1, ERCC2, and XRCC3 and Prognosis in Hepatocellular Carcinoma: A Meta-Analysis
por: Zhao, Yan, et al.
Publicado: (2019)

The Relationship between XRCC1 and XRCC3 Gene Polymorphisms and Lung Cancer Risk in Northeastern Chinese
por: Guo, Shujie, et al.
Publicado: (2013)

Influence of Programmed Death Ligand-1-Gene Polymorphism rs822336 on the Prognosis and Safety of Postoperative Patients with NSCLC Who Received Platinum-Based Adjuvant Chemotherapy
por: Zhao, Ming, et al.
Publicado: (2020)

OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC
por: Hao, Yanzhang, et al.
Publicado: (2014)

XRCC3 Thr241Met gene polymorphisms and lung cancer risk: a meta-analysis
por: Zhan, Ping, et al.
Publicado: (2013)

The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC
por: WANG, YA-DI, et al.
Publicado: (2011)

Reappraisal of XRCC1 Arg194Trp polymorphism and glioma risk: a cumulative meta-analysis
por: Lu, Jun-Ti, et al.
Publicado: (2017)

The effect of downregulation of Stathmin gene on biological behaviors of U373 and U87-MG glioblastoma cells
por: Liu, Ping, et al.
Publicado: (2018)

ERCC1 and XRCC1 but not XPA single nucleotide polymorphisms correlate with response to chemotherapy in endometrial carcinoma
por: Chen, Liang, et al.
Publicado: (2016)

DNA repair genes XRCC1 and XRCC3 polymorphisms and their relationship with the level of micronuclei in breast cancer patients
por: Santos, Raquel A., et al.
Publicado: (2010)

XRCC1 Gene Polymorphisms and Glioma Risk in Chinese Population: A Meta-Analysis
por: He, Li-Wen, et al.
Publicado: (2014)

The XRCC4 rs1805377 polymorphism is not associated with the risk of cancer: An updated meta-analysis
por: Zhang, Xin-yuan, et al.
Publicado: (2020)

A meta-analysis of XRCC1 single nucleotide polymorphism and susceptibility to gynecological malignancies
por: Zhang, Xue Qin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9r1d679j1105t7d7jd16a6dj11